Back to Search
ADIL DAUD, MD
MD
Medical Oncology Physician
NPI: 1699706812IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
ME85033(FL)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
ME85033(DC)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
ME85033(FL)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1986
Research & Publications (20)
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
PMID 19318485·Clin Cancer Res·2009
3-trial
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
PMID 18591558·J Clin Oncol·2008
3-trial
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
PMID 19029422·J Clin Oncol·2008
3-trial
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
PMID 15837755·Clin Cancer Res·2005
3-trial
Comorbidity/overlapping between ADHD and PTSD in relation to IQ among children of traumatized/non-traumatized parents.
PMID 19395643·J Atten Disord·2009
8-other
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
PMID 18682950·Cancer Chemother Pharmacol·2009
3-trial
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
PMID 19434004·Melanoma Res·2009
8-other
The role of etiology in the hyperamylasemia of acute liver failure.
PMID 19223884·Am J Gastroenterol·2009
4-observational
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
PMID 19349552·J Clin Oncol·2009
3-trial
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
PMID 19318486·Clin Cancer Res·2009
3-trial
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.
PMID 18798543·Cancer·2008
6-review
Esophageal dilation after laparoscopic adjustable gastric banding.
PMID 18027041·Surg Endosc·2008
4-observational
Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios.
PMID 18596670·Cancer Control·2008
8-other
Markers of bone and calcium metabolism following gastric bypass and laparoscopic adjustable gastric banding.
PMID 18335295·Obes Surg·2008
4-observational
Resilience and vulnerability among refugee children of traumatized and non-traumatized parents.
PMID 18373846·Child Adolesc Psychiatry Ment Health·2008
8-other
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.
PMID 18442402·BMC Med Genomics·2008
8-other
Trauma, PTSD and personality: the relationship between prolonged traumatization and personality impairments.
PMID 18298618·Scand J Caring Sci·2008
8-other
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
PMID 18824702·J Clin Oncol·2008
3-trial
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
PMID 19088048·Clin Cancer Res·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12902 USF MAGNOLIA DR, MDC 44
TAMPA, FL 33612 - Phone
- (813) 972-8414
Quick Facts
- NPI
- 1699706812
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile